featured
Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection or Ablation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection or Ablation (STORM): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial
Lancet Oncol 2015 Sep 08;[EPub Ahead of Print], J Bruix, T Takayama, V Mazzaferro, GY Chau, J Yang, M Kudo, J Cai, RT Poon, KH Han, WY Tak, HC Lee, T Song, S Roayaie, L Bolondi, KS Lee, M Makuuchi, F Souza, ML Berre, G Meinhardt, JM LlovetFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.